On May 15, 2020 BioInvent International AB ("BioInvent") (OMXS: BINV) reported the presentation of promising new data on its anti-tumor necrosis factor receptor 2 (TNFR2) program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, BioInvent, MAY 15, 2020, View Source [SID1234558172]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key results:
Targeting TNFR2 demonstrates compelling therapeutic effects in syngeneic solid cancer models spanning "hot" and "cold" tumors.
Targeting TNFR2 synergizes with anti-PD-1 to achieve cure.
Careful mechanistic dissection and matching of the human lead clinical candidates and mouse surrogate antibodies enables thorough understanding of TNFR2-targeting and critical guidance of clinical development.
The exciting translational data package will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, taking place June 22-24. The abstract is posted online today.
TNFR2 is particularly upregulated on tumor-associated regulatory T cells (Tregs) and has been shown to be important for their expansion and survival. As a part of its Treg program, BioInvent identified and characterized a wide panel of TNFR2-specific antibodies, generated from its proprietary n-CoDeR library and unique F.I.R.S.TTM discovery tool.
Two antibody variants with distinct molecular and functional properties have been selected for development for treatment of solid cancer based on careful characterization of their mechanisms of action: BI-1808, a ligand-blocking Treg depleting antibody, and BI-1910, a TNFR2 agonist. The two antibody candidates showed strikingly different FcgR-dependence for optimal antitumor activity and – while evoking different initial immune cell mediated events – both elicited transformation of the tumor immune landscape associated with powerful anti-tumor efficacy.
Martin Welschof, CEO of BioInvent, says: "The selection of these promising antibodies is a further demonstration of the efficacy of BioInvent’s proprietary F.I.R.S.T technology platform, a patient-centric approach allowing for the discovery of human antibodies, targets and pathways, using our state-of-the-art n-CoDeR antibody library. These two anti-TNFR2 antibodies displayed potent anti-tumor efficacy across several in vivo cancer models, both as single agents and when combined with anti-PD-1, which make them very exciting compounds for further development."
Title of the poster: "Targeting TNFR2 for Cancer Immunotherapy – Ligand blocking depletors versus receptor agonists"
Authors: Linda Mårtensson, Kirstie Cleary, Monika Semmrich, Mathilda Kovacek, Petra Holmkvist, Caroline Svensson, Mimoza Demiri, Therese Blidberg, Ulla-Carin Thornberg, Vincentiu Pitic, Osman Dadas, Sean H Lim, Stephen A Beers, Mark S Cragg, Björn Frendéus, Ingrid Teige
Abstract Number: 5892
Session Date and Time: June 22-24, 2020
Poster Session Title: Immune Checkpoints 1
Poster Number: 936